Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 1, 2008, Pages 85-96

  Guarcello, Vincenzo ^a   Blanquicett, Carmelo ^a,b   Naguib, Fardos N M ^a   El Kouni, Mahmoud H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer cells; Expression; Promoter methylation; Regulation; Thymidine phosphorylase

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE DEACETYLASE INHIBITOR; LUCIFERASE; MESSENGER RNA; THYMIDINE PHOSPHORYLASE; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRICHOSTATIN A;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REPRESSION; EXON; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INTRON; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM;

BLOTTING, WESTERN; CELL LINE, TUMOR; DNA METHYLATION; DNA PRIMERS; DNA, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EXONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTRONS; NEOPLASM PROTEINS; NEOPLASMS; PROGNOSIS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFITES; THYMIDINE PHOSPHORYLASE;

EID: 42149133142     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0578-5     Document Type: Article

References (47)

1. Ashour OM, Naguib FN, Khalifa MM, Abdel-Raheem MH, Panzica RP, el Kouni MH (1995) Enhancement of 5-fluoro-2′-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside. Cancer Res 55:1092-1098
2. Blanquicett C, Johnson MR, Heslin M, Diasio RB (2002) Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem 303:209-214
3. Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR (2005) Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res 11:8773-8781
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
5. Brown NS, Bicknell R (1998) Thymidine phosphorylase, 2-deoxy-d-ribose and angiogenesis. Biochem J 334(Pt 1):1-8
6. Dannenberg LO, Chen HJ, Tian H, Edenberg HJ (2006) Differential regulation of the alcohol dehydrogenase 1B (ADH1B) and ADH1C genes by DNA methylation and histone deacetylation. Alcohol Clin Exp Res 30:928-937
7. Drexler HG (1998) Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845-859
8. el Kouni MH, el Kouni MM, Naguib FN (1993) Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. Cancer Res 53:3687-3693
9. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
10. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, Harris AL (1995) Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol 176:183-190
11. Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC, Harris AL (1996) The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 73:275-280
12. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y (1992) Angiogenic factor. Nature 356:668
13. Gallo RC, Perry S, Breitman TR (1967) The enzymatic mechanisms for deoxythymidine synthesis in human leukocytes. I. Substrate inhibition by thymine and activation by phosphate or arsenate. J Biol Chem 242:5059-5068
14. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361-6369
15. Heldin C-H, Usuki K, Miyazono K (1991) Platelet-derived endothelial cell growth factor. J Cell Biochem 47:208-210
16. Higley B, Oakes J, De Mello J, Giles GR (1982) Pyrimidine nucleoside phosphorylase activity in tumour and matched normal gastrointestinal mucosa. Gut 23:1072-1076
17. Hotta T, Taniguchi K, Kobayashi Y, Johata K, Sahara M, Naka T, Watanabe T, Ochiai M, Tanimura H, Tsubota YT (2004) Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue. Oncol Rep 12:539-541
18. Imazano Y, Takebayashi Y, Nishiyama K, Akiba S, Miyadera K, Yamada Y, Akiyama S, Ohi Y (1997) Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 15:2570-2578
19. Janion C, Shugar D (1961) Thymidine phosphorylase and other enzymes in regenerating rat liver. Acta Biochim Pol 8:337-344
20. Kaklamanis L, Kakolyris S, Turley H, Koukourakis M, Biddolph S, Gatter KC, Harris AL (1998) Neoplastic stroma and epithelium show up-regulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in colorectal carcinomas but not adenomas. Angiogenesis 2:49-55
21. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC, Harris AL (1997) Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 75:477-481
22. Laird PW, Jaenisch R (1996) The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet 30:441-464
23. Luccioni C, Beaumatin J, Bardot V, Lefrancois D (1994) Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts. Int J Cancer 58:517-522
24. Maehara Y, Moriguchi S, Emi Y, Watanabe A, Kohnoe S, Tsujitani S, Sugimachi K (1990) Comparison of pyrimidine nucleotide synthetic enzymes involved in 5-fluorouracil metabolism between human adenocarcinomas and squamous cell carcinomas. Cancer 66:156-61
25. Miller CR, Gustin AN, Buchsbaum DJ, Vickers SM, Manne U, Grizzle WE, Cloud GA, Diasio RB, Johnson MR (2002) Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. Anal Biochem 301:189-199
26. Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:998-1002
27. Naguib FN, Niedzwicki JG, Iltzsch MH, Wiemann MC, el Kouni MH, Cha SM (1987) Effects of N,N-dimethylformamide and sodium butyrate on enzymes of pyrimidine metabolism in cultured human tumor cells. Leuk Res 11:855-861
28. Niedzwicki JG, el Kouni MH, Chu SH, Cha S (1981) Pyrimidine acyclonucleosides, inhibitors of uridine phosphorylase. Biochem Pharmacol 30:2097-2101
29. Nishino I, Spinazzola A, Papadimitriou A, Hammans S, Steiner I, Hahn CD, Connolly AM, Verloes A, Guimaraes J, Maillard I, Hamano H, Donati MA, Semrad CE, Russell JA, Andreu AL, Hadjigeorgiou GM, Vu TH, Tadesse S, Nygaard TG, Nonaka I, Hirano I, Bonilla E, Rowland LP, DiMauro S, Hirano M (2000) Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 47:792-800
30. Ortmann CA, Burchert A, Holzle K, Nitsche A, Wittig B, Neubauer A, Schmidt M (2005) Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Res 33:6895-6905
31. Pampalakis G, Sotiropoulou G (2006) Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol Chem 387:773-782
32. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N (1999) The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer 81:484-489
33. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297
34. Shaw T, Smillie RH, MacPhee DG (1988) The role of blood platelets in nucleoside metabolism: assay, cellular location and significance of thymidine phosphorylase in human blood. Mutat Res 200:99-116
35. Singal R, Ginder GD (1999) DNA methylation. Blood 93:4059-4070
36. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F, Aikou T (1996) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88:1110-1117
37. Tominaga T, Toi M, Ohashi Y, Abe O (2002) Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients. Clin Breast Cancer 3:55-64
38. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y (2001) A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 18:1190-1202
39. Uchimiya H, Furukawa T, Okamoto M, Nakajima Y, Matsushita S, Ikeda R, Gotanda T, Haraguchi M, Sumizawa T, Ono M, Kuwano M, Kanzaki T, Akiyama S (2002) Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-l-ribose. Cancer Res 62:2834-2839
40. Unoki M, Nakamura Y (2003) Methylation at CpG islands in intron 1 of EGR2 confers enhancer-like activity. FEBS Lett 554:67-72
41. Usuki K, Saras J, Waltenberger J, Miyazono K, Pierce G, Thomason A, Heldin CH (1992) Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun 184:1311-1316
42. van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HF, Peters GJ (2000) Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6:1063-1072
43. Wischnewski F, Pantel K, Schwarzenbach H (2006) Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 4:339-349
44. Woodman PW, Sarrif AM, Heidelberger C (1980) Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2′- deoxyuridine. Cancer Res 40:507-511
45. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW (2006) 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26:77-90
46. Zhu GH, Lenzi M, Schwartz EL (2002) The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells. Oncogene 21:8477-8485
47. Zimmerman M, Seidenberg J (1964) Deoxyribosyl transfer. I. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues. J Biol Chem 239:2618-2621